ISRCTN01751283 https://doi.org/10.1186/ISRCTN01751283

Pulmonary Hypertension in the Intensive Care Unit (ICU) - Swiss Survey 1

Submission date 06/09/2010	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 28/10/2010	**Overall study status** Completed	[_] Statistical analysis plan [_] Results
Last Edited 28/10/2010	**Condition category** Circulatory System	[_] Individual participant data [_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Urs Wenger

Contact details
University Hospital Zürich
Rämistrasse 100
Zürich
Switzerland
8091

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

A prospective multicentre study to investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension in the Intensive Care Unit (ICU)

Acronym
PHICUSS1

Study objectives
To investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension (PH) of any cause in the setting of surgical, medical or interdisciplinary Intensive Care Units (ICUs) of primary, secondary and tertiary Swiss hospitals.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics approval was not required for this study.

Study design
Prospective multicentre study

Primary study design
Observational

Secondary study design
Non randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Screening

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Pulmonary hypertension

Interventions
The current characteristics, local facilities, diagnostic and therapeutic attitude against PH of the participating ICUs are assessed prior to study beginning by a questionnaire (hospital form).

During the study period all consecutive patients admitted to ICU for any reason are screened for presence or suspicion of PH. If PH is present or suspected the most probable causes, diagnostic and therapeutic attitude, clinical, laboratory, haemodynamic data (if measured) and 30 days survival will be assessed by a questionnaire (patient form).

Participating centres are asked to complete the hospital form only once, before study begin. Thereafter, during the enrolment period all patients admitted to the participating ICU are screened by use of the patient from. Only if PH is present, suspected or disclosed at ICU admission, or if risk factors for PH were present, additional information will be requested.

Data collection will be performed online using an electronic form of the data collection sheet.

Intervention Type
Other

Phase
Not Applicable

Primary outcome measure
Prevalence of PH of any cause in the setting of surgical, medical or interdisciplinary ICUs. During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.

Secondary outcome measures
1. Causes of PH in the ICU setting
2. Diagnostic and therapeutic approach to PH by Swiss ICU physicians
3. 30 day outcome of patients admitted to ICU with suspected or confirmed PH

During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.

Overall study start date
01/09/2009

Completion date
30/09/2009

Eligibility

Key inclusion criteria
All consecutive patients (no age limit or gender restrictions) admitted to ICU for any reason

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
1000

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment
01/09/2009

Date of final enrolment
30/09/2009

Locations

Countries of recruitment
Switzerland

Study participating centre
University Hospital Zürich
Zürich
Switzerland
8091

Sponsor information

Organisation
Swiss Society of Pulmonary Hypertension (Switzerland)

Sponsor details
c/o Institut für Medizin und Kommunikation (IMK) AG
Münsterberg 1
Basel
Switzerland
4001

Sponsor type
Research organisation

Website
http://www.imk.ch/Intro/WebHome

ROR
https://ror.org/02c518c71

Funder(s)

Funder type

Research organisation

Funder Name
Swiss Society of Intensive Care Medicine (Switzerland)

Funder Name
Actelion Pharma Schweiz AG (Switzerland)

Funder Name
Lung League Ticino (Switzerland)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration